Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 vs TB-500: Which Is Right for You?

Quick verdict BPC-157 and TB-500 are both prohibited for compounding in the US and have no FDA approval. They are marketed for tissue repair and recovery, with animal data but no completed human trials. Neither is a legal option for human use through US pharma

This comparison does not assign a generated winner or score.

  • Quick verdict
  • BPC-157 and TB-500 are both prohibited for compounding in the US and have no FDA approval. They are marketed for tissue repair and recovery, with animal data but no completed human trials. Neither is a legal option for human use through US pharmacies.
More references

Related material

Comparison

Side-by-Side Comparison

Class Synthetic Fragment Thymosin Peptide FDA Status Research Use Primary Uses Tissue Repair, Recovery Tissue Repair, Recovery, Anti-Inflammation Administration Subcutaneous Injec…

View details →
Comparison

Effectiveness Comparison

Clinical evidence for both peptides remains limited to animal studies, case series, and small observational trials, with no head-to-head comparative studies published in peer-revi…

View details →
Comparison

Cost Comparison

Historical pricing for BPC-157, prior to FDA prohibition, ranged from $80-150 per month for typical dosing protocols when obtained through compounding pharmacies[9]. Research-grad…

View details →
Comparison

BPC-157 vs TB-500

BPC-157 vs TB-500 A 2026 UK research comparison of BPC-157 and TB-500 — two distinct peptides with overlapping preclinical evidence in tendon, ligament and muscle repair. Mechanis…

View details →